Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2106-2114

  Lima, L ^a,b,c,d   Severino, P F ^e,f   Silva, M ^e   Miranda, A ^a,g   Tavares, A ^a   Pereira, S ^a,h   Fernandes, E ^a   Cruz, R ^a   Amaro, T ⁱ   Reis, C A ^b,j   Dall'Olio, F ^f   Amado, F ^g   Videira, P A ^e   Santos, L ^a,h   Ferreira, J A ^a,g  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^d LPCC   (Portugal)

^e UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF AVEIRO   (Portugal)

^h UNIVERSIDADE FERNANDO PESSOA   (Portugal)

ⁱ HOSPITAL PEDRO HISPANO   (Portugal)

^j University of Porto   (Portugal)

more..

Author keywords

Bacillus Calmette Gu rin; BCG immunotherapy; bladder cancer; sialyl 6 T; sialyl Tn; tumour glycosylation

Indexed keywords

BCG VACCINE; CARBOHYDRATE ANTIGEN; SIALYL 6 T; SIALYL TN; UNCLASSIFIED DRUG;

AGE; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER TUMOR; CANCER GROWTH; CELL ADHESION; CELL DEATH; CLINICAL FEATURE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTERNALIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BCG VACCINE; CELL ADHESION; CELL LINE, TUMOR; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCINS; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84885909350     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.571     Document Type: Article

References (32)

1. Ajili F, Manai M, Darouiche A, Chebil M, Boubaker S (2012) Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy. Ultrastruct Pathol 36(5): 320-324.
2. Alexandroff AB, Nicholson S, Patel PM, Jackson AM (2010) Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy 2(4): 551-560.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6): 997-1008.
4. Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacille Calmette- Guerin by bladder tumor cells. J Urol 145(6): 1316-1324.
5. Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression. Urology 63(4): 682-686.
6. Chen F, Zhang G, Iwamoto Y, See WA (2003) Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by cross-linking alpha 5 beta 1 integrin. J Urol 170(2 Pt 1): 605-610.
7. Clement M, Rocher J, Loirand G, Le PJ (2004) Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. J Cell Sci 117(Pt 21): 5059-5069.
8. Dall?Olio F, Malagolini N, Trinchera M, Chiricolo M (2012) Mechanisms of cancer-associated glycosylation changes. Front Biosci 17: 670-699.
9. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA. Club Urologico Espanol de Tratamiento O (2008) Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette- Guerin: Multivariate analysis of data from four randomized CUETO trials. Eur Urol 53(5): 992-1001.
10. Ferreira JA, Videira PA, Lima L, Pereira S, Silva M, Carrascal M, Severino PF, Fernandes E, Almeida A, Costa C, Vitorino R, Amaro T, Oliveira MJ, Reis CA, Dall?Olio F, Amado F, Santos LL (2013) Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol Oncol 7(3): 719-731.
11. Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, Houghton AN, Livingston PO (2007) Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res 13(10): 2977-2985.
12. Joudi FN, Smith BJ, O?Donnell MA, Konety BR (2006) The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175(5): 1634-1639.
13. Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P, Le BX (2006) ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 16(1): 54-64.
14. Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM (2009) Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 100(11): 1746-1754.
15. Kohjimoto Y, Iba A, Shintani Y, Inagaki T, Uekado Y, Hara I (2010) Impact of patient age on outcome following bladder-preserving treatment for nonmuscle- invasive bladder cancer. World J Urol 28(4): 425-430.
16. Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L (2012) Predictive biomarkers of bacillus calmette-guerin immunotherapy response in bladder cancer: where are we now? Adv Urol 2012: 232609.
17. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA (2009) An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscleinvasive bladder cancer. Eur Urol 56(2): 247-256.
18. Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, Almeida R, Silva F, Morais V, Costa J, Kihlberg J, Clausen H, Reis CA (2004) Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 64(19): 7050-7057.
19. Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, Rubens RD (1996) A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 74(8): 1292-1296.
20. O?Boyle KP, Coatsworth S, Anthony G, Ramirez M, Greenwald E, Kaleya R, Steinberg JJ, Dutcher JP, Wiernik PH (2006) Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn. Cancer Immunity 6: 5.
21. Ohno S, Ohno Y, Nakada H, Suzuki N, Soma G, Inoue M (2006) Expression of Tn and sialyl-Tn antigens in endometrial cancer: Its relationship with tumor-produced cyclooxygenase-2, tumor-infiltrated lymphocytes and patient prognosis. Anticancer Res 26(6A): 4047-4053.
22. Oosterlinck W, van der Meijden A, Sylvester R, Bo?hle A, Rintala E, Solsona Narvón E, Lobel B (2006) Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer.
23. Office EG (ed). EAU Guidelines Office: Arnhem, The Netherlands. Palou Redorta J (2006)
24. Management of BCG ?Failures?. Eur Urol 49(5): 779-780.
25. Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, Harduin-Lepers A, Reis CA (2007) Biological significance of cancerassociated sialyl-Tn antigen: Modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett 249(2): 157-170.
26. Ratliff TL (1992) Role of the immune response in BCG for bladder cancer. Eur Urol 21(Suppl 2): 17-21.
27. Schneider B, Thanhauser A, Jocham D, Loppnow H, Vollmer E, Galle J, Flad HD, Ulmer AJ, Bohle A (1994) Specific binding of bacillus Calmette- Guerin to urothelial tumor cells in vitro. World J Urol 12 6: 337-344.
28. Sinn HW, Elzey BD, Jensen RJ, Zhao X, Zhao W, Ratliff TL (2008) The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity. Cancer Immunol Immunother 57(4): 573-579.
29. Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T (2013) The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology 23(2): 178-187.
30. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 56 3: 430-442.
31. Videira PA, Correia M, Malagolini N, Crespo HJ, Ligeiro D, Calais FM, Trindade H, Dall?Olio F (2009) ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 9: 357.
32. Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH, Zwarthoff EC (2012) Markers predicting response to bacillus Calmette- Guerin immunotherapy in high-risk bladder cancer patients: A systematic review. Eur Urol 61(1): 128-145.